<table id="i5506059d-bbf2-4de2-8a2e-11745a8b9283" width="60%" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption>Table 2 Dose to body weight range to achieve similar steady-state exposure (AUC<sub>0–24hr</sub>) to unbound oxaprozin in JRA patients relative to 70 kg adult rheumatoid arthritis patients administered oxaprozin 1200 mg QD<footnote>Model-based nomogram derived from unbound oxaprozin steady-state drug plasma concentrations of JRA patients weighing 22.1 – 42.7 kg or ≥45.0 kg administered oxaprozin 600 mg or 1200 mg QD for 14 days, respectively.</footnote>
</caption>
<col align="center" valign="middle" width="50%"></col>
<col align="center" valign="middle" width="50%"></col>
<thead>
<tr>
<th>Dose (mg)</th>
<th>Body WeightRange (kg)</th>
</tr>
</thead>
<tbody>
<tr stylecode="Botrule">
<td>600</td>
<td>22 –31</td>
</tr>
<tr stylecode="Botrule">
<td>900</td>
<td>32 –54</td>
</tr>
<tr>
<td>1200</td>
<td>≥ 55</td>
</tr>
</tbody>
</table>